Foster and Wood Join Board of Directors

SpineThera, a privately held, pre-clinical stage pharmaceutical company, announced that John Foster and David Wood have joined its Board of Directors.

Mr. Foster previously led CNS Therapeutics through development of a 505(b)2 pain drug for site-specific administration to the central nervous system to treat intractable chronic pain. CNS was acquired by Mallinckrodt. He is currently the CEO and Chairman of NTF Therapeutics and Vice Chairman of Gillette Children's Specialty Healthcare. Jeff Missling, Chairman and CEO of SpineThera, said, "John's success in commercializing injectable drugs is directly relevant to SpineThera. He brings strong knowledge of clinical, commercial, and regulatory processes to our Board." 

Mr. Wood previously led Spinal Modulation through commercialization of a novel, implantable neuro-stimulator designed to treat intractable neuropathic pain. Spinal Modulation was acquired by St. Jude Medical. John was previously the COO of CardioNet and VP and General Manager of the Drug Delivery Business Unit at SurModics. Mr. Missling said, "Dave has excellent relationships with leading Interventional Pain physicians in the United States and abroad. He is above all a strategist with a keen focus on speed and execution." 

Foster and Wood join Mr. Jerry Jerome and Mr. Wayne Kelly on SpineThera's Board. Missling commented, "I am delighted and grateful to have John and Dave join SpineThera's Board. They both have a track record of raising significant capital from venture firms and strategic partners, and of leading a start-up through the acquisition process. In addition, they bring relevant experience from pain medicine product development. They undoubtedly strengthen SpineThera's board and position us for longer term success."